Early TRAIL-engagement elicits potent multimodal targeting of melanoma by CD34+ progenitor cell-derived NK cells

Vliet, Amanda A. van; Peters, Ella; Vodegel, Denise; Steenmans, Daniëlle; Raimo, Monica; Gibbs, S.; Gruijl, Tanja D. de; Duru, Adil Doğanay; Spanholtz, Jan; Georgoudaki, Anna‐Maria

doi:10.1016/j.isci.2023.107078

Cited by 4 publications

(2 citation statements)

References 51 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TRAIL play a crucial role both during viral clearance [ 202 , 203 , 204 , 205 , 206 , 207 , 208 , 209 , 210 , 211 , 212 , 213 , 214 ] and tumour immune surveillance [ 215 , 216 , 217 , 218 , 219 , 220 ]. Mechanistically, during innate immunity, NK cells and CTLs (cytotoxic T cells) promote apoptosis of target cells, either by releasing soluble factors such as the cytolytic granules [ 184 , 221 , 222 , 223 ], which contain perforin and granzymes, or by engaging membrane-bound death ligands like FasL or TRAIL [ 200 , 221 , 224 , 225 , 226 , 227 , 228 , 229 ].…”

Section: Physiological and Physiopathological Functions Of Trailmentioning

confidence: 99%

TNF-Related Apoptosis-Inducing Ligand: Non-Apoptotic Signalling

Guerrache,

Micheau

2024

Cells

View full text Add to dashboard Cite

TNF-related apoptosis-inducing ligand (TRAIL or Apo2 or TNFSF10) belongs to the TNF superfamily. When bound to its agonistic receptors, TRAIL can induce apoptosis in tumour cells, while sparing healthy cells. Over the last three decades, this tumour selectivity has prompted many studies aiming at evaluating the anti-tumoral potential of TRAIL or its derivatives. Although most of these attempts have failed, so far, novel formulations are still being evaluated. However, emerging evidence indicates that TRAIL can also trigger a non-canonical signal transduction pathway that is likely to be detrimental for its use in oncology. Likewise, an increasing number of studies suggest that in some circumstances TRAIL can induce, via Death receptor 5 (DR5), tumour cell motility, potentially leading to and contributing to tumour metastasis. While the pro-apoptotic signal transduction machinery of TRAIL is well known from a mechanistic point of view, that of the non-canonical pathway is less understood. In this study, we the current state of knowledge of TRAIL non-canonical signalling.

show abstract

Section: Physiological and Physiopathological Functions Of Trailmentioning

confidence: 99%

TNF-Related Apoptosis-Inducing Ligand: Non-Apoptotic Signalling

Guerrache,

Micheau

2024

Cells

View full text Add to dashboard Cite

show abstract

“…TRAIL play a crucial role both during viral clearance [202][203][204][205][206][207][208][209][210][211][212][213][214] and tumour immune surveillance [215][216][217][218][219][220]. Mechanistically, during innate immunity, NK cells and CTLs (cytotoxic T cells) promote apoptosis of target cells, either by releasing soluble factors such as the cytolytic granules [184,[221][222][223], which contain perforin and granzymes, or by engaging membranebound death ligands like FasL or TRAIL [200,221,[224][225][226][227][228][229].…”

Section: Physiological and Physiopathological Functions Of Trailmentioning

confidence: 99%

TRAIL-Non-Apoptotic Signalling

Guerrache,

Micheau

2024

Preprint

View full text Add to dashboard Cite

TNF-related apoptosis-inducing ligand (TRAIL or Apo2 or TNFSF10) belongs to the TNF superfamily. When bound to its agonistic receptors, TRAIL can induce apoptosis in tumour cells, while sparing healthy cells. This tumour selectivity prompted, over the last three decades, many studies aiming at evaluating the anti-tumoral potential of TRAIL or its derivatives. Although most of these attempts have failed, so far, novel formulations are still being evaluated. Yet, emerging evidence indicates that TRAIL can also trigger, on the other hand, a non-canonical signal transduction pathway that is likely to be detrimental for its use in oncology. Likewise, increasing studies suggest that TRAIL can induce, through Death receptor 5 (DR5) in some circumstances, tumour cell motility, potentially leading to and contributing to tumour metastasis. While the pro-apoptotic signal transduction machinery of TRAIL is well known from a mechanistic point of view, that of the non-canonical pathway is less understood. We are reviewing here the current state of knowledge of TRAIL non-canonical signalling.

show abstract